About this raise

NowRx, with a valuation of $6 million, is raising funds on SeedInvest. It is a pharmacy delivery solution that uses advanced technology to provide free same-day delivery for all prescription needs. NowRx’s on-demand delivery model offers convenience, higher worker productivity, and superior customer experience. The platform has filled thousands of prescriptions and served multiple customers since its launch. Cary Breese and Sumeet Shoekand founded NowRx in February 2015. The current crowdfunding campaign has a minimum target of $100,000 and a maximum target of $1 million. The campaign proceeds will be used for software, sales, and marketing.

Expand

Investment Overview

Invested this round: $209,230

Deal Terms

Platform
SeedInvest
Start Date
04/04/2017
Close Date
07/19/2017
Min. Goal
$100,000
Max Goal
$1,000,000
Min. Investment

$500

Security Type

Convertible Note

Company Stage

Early Stage

SEC Filing Type

RegCF / RegD 506(c)    Open SEC Filing

Valuation Cap

$6,000,000

Discount

20%

Company & Team

Company

Year Founded
2015
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Location
Mountain View, California
Company Website
Visit Website

Team

Funding data not publicly available

Financials

 Revenue
$0
as of FY2016
 Monthly Burn
$48,620
as of FY2016
 Runway
3.3 months
as of FY2016
 Gross Margin
18%
as of FY2016

Summary Profit and Loss Statement

FY 2016 FY 2015

Revenue

$700,551

$0

COGS

$572,549

$0

Tax

$0

$0

 

 

Net Income

$-583,438

$-247,240

Summary Balance Sheet

FY 2016 FY 2015

Cash

$159,519

$160,765

Accounts Receivable

$178,098

$12,826

Total Assets

$498,583

$308,161

Short-Term Debt

$210,911

$109,551

Long-Term Debt

$1,117,500

$445,000

Total Liabilities

$1,328,411

$554,551

Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Company Funding & Growth

Funding history

Close Date Platform Valuation Total Raised Security Type Status Reg Type
05/20/2022 SeedInvest $275,000,000 $30,006,323 Equity - Preferred Funded RegA+
10/05/2021 SeedInvest $275,000,000 $3,635,310 Equity - Preferred Funded Test the Waters / RegA+
06/19/2020 SeedInvest $65,000,000 $20,002,878 Equity - Preferred Funded RegA+
06/30/2018 SeedInvest $20,000,000 - Equity - Preferred Funded RegA+
07/19/2017 SeedInvest $6,000,000 $209,230 Convertible Note Funded RegCF / RegD 506(c)
Create a free account today to gain access to Kingscrowd analytics.

Growth Charts

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
NowRx on SeedInvest 2017
Platform: SeedInvest
Security Type: Convertible Note
Valuation: $6,000,000

Follow company

Follow NowRx on SeedInvest 2017

Buy NowRx's Deal Report

Warning: according to the close date for this deal, NowRx may no longer be accepting investments.

NowRx Deal Report

Get Kingscrowd's comprehensive report on NowRx including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether NowRx is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the NowRx deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge